Our patients at Ivm : Real-world data from our GLP-1 ID program shows 19.5% average weight loss at 52 weeks
Async messaging with a licensed providerGet expert guidance anytime at no extra cost
Periprocedural Management of Glucagon-like Peptide-1 Receptorbased Agonists (GLP1ra) in Patients with Diabetes and Obesity Androgenetic Alopecia: Pathogenesis, Evaluation, and Management Special Supplement, Fall 2025 Addressing Metabolic DysfunctionAssociated Steatotic Liver Disease (MASLD) in Endocrinology Settings in Canada: From Prevalence to Patient-Centered Management Volume 3, Issue 3, Fall 2025 Optimizing the Use of Automated Insulin Delivery (AID) Systems in Routine Clinical Care of People with Type 1 Diabetes Ilana Halperin, MD, MSc, FRCPC Youth-Onset Type 2 Diabetes: A Review Running a Trans-Welcoming Clinical Practice Novel Treatment Options For Menopausal Symptoms Volume 3, Issue 2, Summer 2025 Autoantibodies in Type 1 Diabetes Current and Emerging Treatments For the Management of Hypoparathyroidism Vaccinating Your Adult Diabetic Patient: What Vaccines Would You Recommend

Over-pressuring the vial: Injecting more water volume than the vial can hold creates excess pressure and risks contamination
(PubMed) Chalasani NP, Sanyal AJ, Kowdley KV, et al